Back to search
Publication

Elimination of lymphatic filariasis: current perspectives on mass drug administration.

Abstract
Following the London declaration on neglected tropical diseases (NTDs) in 2012 and inspired by the WHO 2020 roadmap to control or eliminate NTDs, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) intensified preventive chemotherapy and management of morbidity as the two main strategies to enhance progress towards the elimination of lymphatic filariasis (LF). This paper focuses on current perspectives of mass drug administration (MDA) towards the elimination of LF. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector. Three drugs, diethylcarbamazine, albendazole, and ivermectin are currently available for LF treatment, and their effectiveness and relative safety have opened the possibility of treating the entire population at risk. Currently, almost all LF endemic countries rely on the single-dose two-drug regimen recommended by the GPELF to achieve elimination. The 4th WHO report on NTDs has indicated that considerable progress has been made towards elimination of LF in some countries while acknowledging some challenges. In this review, we conclude that the 2020 elimination goal can be achieved if issues pertaining to the drug distribution, health system and implementation challenges are addressed.

More information

Type
Journal Article
Author
Gyapong JO
Owusu IO
Vroom FB
Mensah EO
Gyapong M
Year of Publication
2018
Journal
Research and Reports in Tropical Medicine
Volume
Volume 9
Number of Pages
18-33
Language
eng
DOI
10.2147/RRTM10.2147/RRTM.S125204
Alternate Journal
RRTM
Publication Language
eng